“The markets are dead!”: Emerita Resources (EMO.V) shows otherwise with massive upside coming
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we focus on Medexus Pharma (MDP.T), a Canadian specialty pharma firm bringing new therapeutic drugs to the Canadian market for use in such areas as rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases.
Enjoy!
